Adalimumab as a adjuvant therapy in modrate to sever MDD

Phase 3

• Conditions: Major Depressive Disorder.; Major depressive disorder, single episode, moderate; F32.1

• Registration Number: IRCT20090117001556N121
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Presence of Major Depressive Disorder based on DSM-5 criteria
Baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 19
CRP equals or more than 3mg/lit

Exclusion Criteria

Psychotic symptoms
Any other mental disorder
Hypothyroidism
Cardiovascular disease
Pregnant or nursing women
History of tuberculosis
Autoimmune disease
Viral hepatitis
Chronic or recurrent infections
Receiving ECT during the last two months
Significant suicidal ideation
Substance use
HIV

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of depression. Timepoint: Baseline and weeks 2,4 and 6. Method of measurement: By Hamiltion Depression Rating Scale 17-Item.